Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 28, 2015
Pharmacy Choice - News - U.S. Pharmaceutical Industry - May 28, 2015

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

5/28/15 - "Supporting Structure for Concurrently Supporting a Plurality of Containers for Substances for Medical, Pharmaceutical Or Cosmetic Applications" in...
"Supporting Structure for Concurrently Supporting a Plurality of Containers for Substances for Medical, Pharmaceutical Or Cosmetic Applications" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Politics& Government Week A patent application by the inventors Deutschle, Gregor Fritz; Pawlowski, Edgar; Wassenberg, Joem
5/28/15 - 2015 BHR Pharma LLC - Product Pipeline Review Market Share
Most up-to-date research on " BHR Pharma LLC- Product Pipeline Review- 2015" to its huge collection of research reports.Albany, NY 05/28/2015 Global Markets Directs, BHR Pharma, LLC Product Pipeline Review 2015, provides an overview of the BHR Pharma, LLCs pharmaceutical research and development focus. This report provides comprehensive infor
5/28/15 - AARP survey: Prices fell for most generic drugs seniors use, but dozens rose 10 pct.-1000 pct.
TRENTON, N.J. Reversing a long-term trend, prices for more than one in four generic medicines widely used by older Americans increased in 2013, some very sharply, according to a survey by AARP.
5/28/15 - Actinium Clinical Update on Actimab-A Provided at Targeted Alpha Therapy Symposium
Actinium Pharmaceuticals, Inc., a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, recently sponsored the 9 th Symposium on Targeted Alpha Therapy, held in Warsaw, Poland on May 19-21. Symposium organizers included the Institute for Transuranium Elements of the European...
5/28/15 - Actinium Offers Clinical Update on Actimab-A Provided at Targeted Alpha Therapy Symposium
Actinium Pharmaceuticals, Inc., a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, recently sponsored the 9th Symposium on Targeted Alpha Therapy, held in Warsaw, Poland on May 19-21. Symposium organizers included the Institute for Transuranium Elements of the European...
5/28/15 - Agile Therapeutics to Present at the William Blair 35th Annual Growth Stock Conference
Agile Therapeutics, Inc. a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that Al Altomari, President and Chief Executive Officer will present at the William Blair 35 th Annual Growth Stock Conference on June 9, 2015 at 2:10 PM Central Ti
5/28/15 - Altor BioScience Announces Upcoming Data Presentation on Efficacy and Safety of ALT-801 for Advanced Bladder Cancer at 2015 ASCO Annual Meeting
Altor has concluded two Phase 1/ 2 clinical studies of ALT-801 in combination with gemcitabine and cisplatin or gemcitabine alone in patients with advanced/metastatic urothelial cancer. Altor is also conducting a clinical trial of ALT-801 in combination with gemcitabine in patients with Bacillus Calmette Guerin- resistant non-muscle-invasive...
5/28/15 - AMAG Pharmaceuticals Receives Complete Response Letter From FDA for the Single-Dose Vial of Makena(R) (Hydroxyprogesterone Caproate Injection)
AMAG Pharmaceuticals, Inc., today announced that it has received a complete response letter from the U.S. Food and Drug Administration regarding its manufacturing supplement seeking approval for a single-dose vial of Makena. A complete response letter is a communication from the FDA that informs companies that an application cannot be approved in
5/28/15 - Amarin Granted Summary Judgment Motion in Suit Against FDA Seeking New Chemical Entity Market Exclusivity for Vascepa(R) (Icosapent Ethyl) Capsules
BEDMINSTER, NJ and DUBLIN, IRELAND 05/28/15 Amarin Corporation plc, announced today that Judge Randolph D. Moss of the federal district court for the District of Columbia has granted Amarin's motion for summary judgment in the company's lawsuit against the United States Food and Drug Administration seeking an order requiring FDA to recognize
5/28/15 - Analytical Strategies for Drug Development Seminar in Cambridge
Regis Technologies will host a technical talk in Cambridge, MA delivered by their Director of Analytical Method Development, Paul Wrezel, Ph.D. Dr. Wrezel will answer important questions, such as:? What analytical data is required in order to be granted permission for a clinical trial or commercial distribution? Dr. Wrezel will also provide indus
5/28/15 - Archer Pharmaceuticals Inc - Product Pipeline Review 2015
Most up-to-date research on " Archer Pharmaceuticals Inc- Product Pipeline Review- 2015" to its huge collection of research reports.Albany, NY 05/28/2015 Global Markets Directs, Archer Pharmaceuticals, Inc. Product Pipeline Review 2015, provides an overview of the Archer Pharmaceuticals, Inc.s pharmaceutical research and development focus.
5/28/15 - ARUP Laboratories and Labceutics Form Strategic Alliance to Better Serve Personalized Healthcare Market
ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, and Labceutics, a global solutions provider to the pharmaceutical industry focused on optimizing the laboratory physician interface, announced today the formation of a unique strategic alliance
5/28/15 - Asubio Pharma Co Ltd - Product Pipeline Review 2015 Research Report
Most up-to-date research on " Asubio Pharma Co Ltd- Product Pipeline Review- 2015" to its huge collection of research reports.Albany, NY 05/28/2015 Global Markets Directs, Asubio Pharma Co., Ltd. Product Pipeline Review 2015, provides an overview of the Asubio Pharma Co., Ltd.s pharmaceutical research and development focus. This report provid
5/28/15 - AVEO Oncology to Present Final Results of Extension Study 902 and FDA Regulatory Feedback for Advancing Tivozanib in Renal Cell Carcinoma [Professional Services Close - Up]
AVEO Oncology reported that final results from the TIVO -1 extension study, known as Study 902, in which patients with advanced renal cell carcinoma received tivozanib as second-line treatment subsequent to disease progression on sorafenib in the Company's Phase 3 TIVO -1 first-line RCC study, will be presented at the 2015 American Society of Clini
5/28/15 - Catalyst Pharmaceuticals Names Richard J. Daly Interim Chief Commercial Officer
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the appointment of Richard J. Daly to the position of interim Chief Commercial Officer. "David helped Catalyst with important progress in our pre-commercialization.
5/28/15 - Cavion to Present Clinical Trial Data at ASCO
Cavion LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors and neurologic diseases, announced today that Matthias Holdhoff, MD, PhD of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins will present preliminary results from an ongoing multi-site National Cancer Institute Adult Bra
5/28/15 - Cellceutix to Present Poster on Kevetrin, a Novel p53 Targeted Therapy for Solid Tumors at American Society of Clinical Oncology (ASCO) Annual Meeting
Cellceutix Corporation, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today announced that the Company will be sponsoring an abstract publication at the American Society of Clinical Oncology 2015 Annual Meeting being held May 29- June 2, 2015 at.
5/28/15 - Celldex Therapeutics Initiates Phase 1/2 Study Of Varlilumab
WASHINGTON- Celldex Therapeutics, Inc. announced the initiation of an open-label, Phase 1/ 2 safety and tolerability study examining the investigational combination of varlilumab and sunitinib or SUTENT in patients with metastatic clear cell renal cell carcinoma or CC-RCC. Varlilumab is Celldex's fully human monoclonal agonist antibody that binds a
5/28/15 - Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Sunitinib in Metastatic Clear Cell Renal Cell Carcinoma
Celldex Therapeutics, Inc. today announced the initiation of an open-label, Phase 1/ 2 safety and tolerability study examining the investigational combination of varlilumab and sunitinib in patients with metastatic clear cell renal cell carcinoma. Sunitinib is approved by the FDA as monotherapy for the treatment of advanced renal cell carcinoma,
5/28/15 - Cocrystal Pharma to Present at Jefferies 2015 Global Healthcare Conference
BOTHELL, WA and ATLANTA, GA 05/28/15 Cocrystal Pharma, Inc., a company focused on developing novel antiviral therapeutics for human diseases, announced today that it will be presenting at the Jefferies 2015 Global Healthcare Conference on Thursday, June 4, 2015 from 12:30 p.m. to 1:00 p.m. at the Grand Hyatt in New York, New York. About Cocry
5/28/15 - Cour Pharmaceuticals To Announce New Breakthrough Data on Treatment for Celiac Disease
For all media inquiries, please email Greg Roberts at groberts@courpharma.com. About Cour: Cour Pharmaceutical Development Company Inc., a private development stage biopharmaceutical company, was founded to develop innovative nanobiological therapeutics for acute inflammation, autoimmunity and allergic conditions based on scientific research...
5/28/15 - D&A Pharma SAS - Product Pipeline Review 2015
Most up-to-date research on "D&A Pharma SAS- Product Pipeline Review- 2015" to its huge collection of research reports.Albany, NY 05/28/2015 Global Markets Directs, D&A Pharma SAS Product Pipeline Review 2015, provides an overview of the D&A Pharma SASs pharmaceutical research and development focus. This report provides comprehensive informat
5/28/15 - Embera NeuroTherapeutics Initiates Phase 1 Clinical Trial to Test EMB-001 as a Novel Treatment for Addictions
BOSTON& SHREVEPORT, La. Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for smoking cessation, cocaine use disorder and other addictions, today announced the first subject received the initial dose in a Phase 1 clinical trial evaluating EMB-001. A novel combination of the FDA- approved drugs metyra
5/28/15 - European Medicines Agency Validates Gilead's Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment
Gilead Sciences, Inc. today announced that the company s Marketing Authorization Application for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide has been fully validated and is now under evaluation by the European Medicines Agency. Therapy innovations have transformed HIV into a chronic condit
5/28/15 - FDA Approves IBS-D Drugs, GBIM Plunges On Hepatitis B Drug Data, RTRX On A High
WASHINGTON- Valeant Pharmaceuticals International Inc.' s wholly owned subsidiary, Salix Pharmaceuticals Inc., has received FDA approval for Xifaxan 550 mg for the treatment of irritable bowel syndrome with diarrhea in adults. Sales of Xifaxan 550 mg during the first four full quarters following the expanded approval approval are expected to be bet
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415